FOSUN 复星

復星國際有限公司

FOSUN INTERNATIONAL LIMITED

(Incorporated in Hong Kong with limited liability)

(Stock Code: 00656)

PROPOSED SPIN-OFF AND SEPARATE LISTING OF FOSUN ADGENVAX ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE

This announcement is made by Fosun International Limited (the "**Company**") pursuant to Practice Note 15 ("**Practice Note 15**") of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the "**Hong Kong Stock Exchange**") (the "**Hong Kong Listing Rules**").

LISTING APPLICATION AND APPLICATION PROOF

The board of directors of the Company are pleased to announce that the Company and its subsidiary Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司, "**Fosun Pharma**") have made a joint application to the Hong Kong Stock Exchange pursuant to Practice Note 15 for the approval of the proposed spin-off of Fosun Adgenvax (Chengdu) Biopharmaceutical Co., Ltd.* (復星安特金（成都）生物製藥股份有限公司, "**Fosun Adgenvax**"), a subsidiary of Fosun Pharma, for listing on the Main Board of the Hong Kong Stock Exchange (the "**Proposed Spin-off Listing**") and the Hong Kong Stock Exchange has confirmed that the Company and Fosun Pharma may proceed with the Proposed Spin-off Listing.

The Company was informed that Fosun Adgenvax has submitted a listing application through its joint sponsors to the Hong Kong Stock Exchange on 26 June 2026, to apply for the listing of, and the permission to deal in, the H shares of Fosun Adgenvax on the Main Board of the Hong Kong Stock Exchange.

The application proof, redacted as required, of Fosun Adgenvax's prospectus (the "**Application Proof**") is available for reviewing and downloading on the website of the Hong Kong Stock Exchange (https://www1.hkexnews.hk/app/appindex.html).

The Application Proof contains, among other things, certain business and financial information relating to Fosun Adgenvax. Shareholders and potential investors of the Company should note that the Application Proof is in draft form and the information contained in it is incomplete and is subject to change which can be material. The Company shall not have any obligation or liability whatsoever in relation to the contents of the Application Proof.

As disclosed in the circular of Fosun Pharma dated 4 February 2026, the initial size of the initial public offering of shares and listing on the Main Board of the Hong Kong Stock Exchange of Fosun Adgenvax (the "**Proposed Issuance of Fosun Adgenvax**") shall not exceed 25% of the enlarged total share capital of Fosun Adgenvax immediately after the issuance, and the global coordinator(s) or bookrunner(s) shall be granted an over-allotment option not exceeding 15% of the aforementioned initial issuance size. It is estimated that upon completion of the Proposed Spin-off Listing, Fosun Adgenvax will remain as a subsidiary of Fosun Pharma and the Company.

GENERAL

Pursuant to the requirements under the Practice Note 15, the Company is required to have due regard to the interests of its existing shareholders by providing them with an assured entitlement to the H shares to be issued by Fosun Adgenvax (the "**Assured Entitlement**") by way of a preferential application if the Proposed Spin-off Listing proceeds, subject to certain conditions, including the filing or approval of the China Securities Regulatory Commission (the "**CSRC**"), the Hong Kong Stock Exchange and other regulatory authorities for the Proposed Spin-off Listing. The terms of such Assured Entitlement have not been finalised but in any event all the qualifying shareholders of the Company will be treated equally. The Company will make further announcements in this regard as and when appropriate pursuant to the Hong Kong Listing Rules.

In connection with the Proposed Issuance of Fosun Adgenvax, the price of the H shares of Fosun Adgenvax may be stabilised in accordance with the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong). Details of any intended stabilisation and how it will be regulated under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) will be contained in the prospectus of Fosun Adgenvax, which will be issued in Hong

Kong in connection with the Proposed Issuance of Fosun Adgenvax, if the Proposed Spin-off Listing proceeds.

As the highest of the applicable percentage ratios (as defined in the Hong Kong Listing Rules) in respect of the Proposed Spin-off Listing shall be less than 5%, the Proposed Spin-off Listing, if it proceeds, is expected not to constitute a notifiable transaction for the Company under the Hong Kong Listing Rules.

The Proposed Spin-off Listing is subject to, among other things, the filing or approval of the CSRC, the Hong Kong Stock Exchange and other relevant regulatory authorities, the market conditions and other factors, and there is no assurance on the aforesaid filing or approval. Therefore, Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. Any person who is in doubt about his/her/its position or any action to be taken is recommended to consult his/her/its own professional advisors.

Further announcements will be made by the Company in respect of the Proposed Spin-off Listing as and when appropriate.

By Order of the Board
Fosun International Limited
Guo Guangchang
Chairman

26 June 2026

As at the date of this announcement, the executive directors of the Company are Mr. Guo Guangchang, Mr. Wang Qunbin, Mr. Chen Qiyu, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Huang Zhen and Mr. Pan Donghui; the non-executive directors are Mr. Li Fuhua and Mr. Luo Yuanli; and the independent non-executive directors are Mr. Zhang Shengman, Mr. Zhang Huaqiao, Mr. David T. Zhang, Dr. Lee Kai-Fu and Ms. Tsang King Suen Katherine.

** for identification purposes only.*